Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN057 Long-term Prophylaxis in Hemophilia A or B
NCT07545395Phase 3Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Armocibart in hemophilia A, hemophilia B (HB), sponsored by Alphamab Oncology. Started Mar 2026; status: recruiting.
02
Drugs
Armocibart
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT07545395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545395.